Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? (2019) Merola E, Rinke A, Partelli S, Gress TM, Andreasi V, Kollar A, Perren A, et al. Journal article Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE (2019) Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, Pavel ME, Prasad V Journal article Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study (2019) Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al. Journal article, Review article Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms (2019) Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, et al. Journal article Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study (2019) Lamarca A, Ronot M, Moall S, Crona J, Opalinska M, Lopez C, Pezzutti D, et al. Conference contribution Treatment Strategies Derived from Comprehensive Genomic and Transcriptomic Analysis in Patients with Advanced-Stage Neuroendocrine Neoplasms: Results from the MASTER Trial of the German Cancer Consortium (2019) Apostolidis L, Kreutzfeldt S, Oles M, Heining C, Hutter B, Gieldon L, Lamping M, et al. Conference contribution Immunoprofiling in Neuroendocrine Neoplasms: Implications for Immunotherapy (2019) Busse A, Spenke C, Arsenic R, Briest F, Sipos B, Kaemmerer D, Pavel ME, et al. Conference contribution Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study (2019) Pavel ME, Dromain C, Thanh TXM, Houchard A Conference contribution Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms (2018) Apostolidis L, Kreutzfeldt S, Oles M, Gieldon L, Heining C, Horak P, Hutter B, et al. Conference contribution